Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.
The issue of pharmacoresistance in epilepsy has received considerable attention in recent years, and a number of plausible hypotheses have been proposed. Of these, the so-called transporter hypothesis is the most extensively researched and documented. This hypothesis assumes that refractory epilepsy is associated with a localised over-expression of drug transporter proteins such as P-glycoprotein (Pgp) in the region of the epileptic focus, which actively extrudes antiepileptic drugs (AEDs) from their intended site of action. However, although this hypothesis has biological plausibility, there is no clinical evidence to support the assertion that AEDs are sufficiently strong substrates for transporter-mediated extrusion from the brain. The use of modern brain imaging techniques to determine Pgp function in patients with refractory epilepsy has started only recently, and may ultimately determine whether increased expression and function of Pgp or other efflux transporters are involved in AED resistance.
Löscher
Wolfgang
W
Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Bünteweg 17, D-30559 Hannover, Germany. wolfgang.loescher@tiho-hannover.de
Langer
Oliver
O
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics* / Q000378:metabolism*; D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D004827:Epilepsy / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D049268:Positron-Emission Tomography
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000927:Anticonvulsants